EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020)

Disclaimer The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

1. Архипова О.А., Мартынюк Т.В., Самойленко Л.Е., др. Перфузионная сцинтиграфия легких у больных с легочной гипертензией различной этиологии. Евразийский кардиологический журнал 2015; 4: 21-25.

2. Белевская А.А., Дадачева З.Х., Саидова М.А., др. Возможности эхокардиографии в диагностике легочной гипертензии и оценке ремоделирования сердца. Лечебное дело. 2015; 1: 111-121.

3. Блинова Е.В., Сахнова Т.А., Мартынюк Т.В., др. Сопоставление векторкардиографических параметров со структурно-функциональным состоянием правого желудочка у пациентов с легочной гипертензией. Системные гипертензии. 2015; 4: 57-60.

4. Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Баллонная ангиопластика легочных артерий при неоперабельной хронической тромбоэмболической легочной гипертензии. Сonsilium Medicum 2016; 5: 59-61.

5. Валиева З.С., Грацианская С.Е., Мартынюк Т.В. Применение риоцигуата для лечения пациентов с хронической тромбоэмболической легочной гипертензией. Кардиология 2020; 60 (8): 115-123. DOI: 10.18087/cardio.2020.8.n1198

6. Веселова Т.Н., Демченкова А.Ю., Мартынюк Т.В., др. Субтракционная КТ-ангиопульмонография в диагностике хронической тромбоэмболической легочной гипертензии. Медицинская визуализация 2018; 4: 40-49. doi.org/10.24835/1607-0763-2018-4-40-49

7. Газизов В.В., Мершин К.В., Табакьян Е.А., др. Результаты легочной тромбэндартерэктомии в зависимости от величины легочного сосудистого сопротивления и ангиографического индекса поражения легочной артерии. Системные гипертензии 2020; 17 (1): 62-68. DOI: 10.26442/2075082X.2020.1.200040

8. Демченкова А.Ю., Веселова Т.Н., Мартынюк Т.В., др. Состояние сосудистого русла, паренхимы и перфузии легких при хронической тромбоэмболической легочной гипертензии по данным субтракционной компьютерной томографической ангиопульмонографии. Кардиология 2018; 58 (5): 48-56. doi.org/10.18087/cardio.2018.5.10120

9. Карабашева М.Б., Данилов Н.М., Сагайдак О.В., др. Отдаленные результаты ангиопластики легочных артерий у пациентов с неоперабельной ХТЭЛГ. Системные гипертензии 2019; 16 (4):27-32. DOI: 10.26442/2075082X.2019.4.190609

10. Клименко А.А., Шостак Н.А., Демидова Н.А., Новиков И.В. Хроническая постэмболическая легочная гипертензия: новые аспекты формирования и прогрессирования заболевания. Клиницист 2011; 5 (1):14–17. doi.org/10.17650/1818-8338-2011-1-14-17

11. Мартынюк Т.В., Чазова И.Е. Илопрост— ингаляционный аналог простациклина для лечения больных легочной гипертензией. Системные гипертензии 2011; 4: 57–63.

12. Мартынюк Т.В., Дадачева З.Х., Парамонов В.М., др. Применение ингибитора фосфодиэстеразы типа 5 силденафила у больных с легочной гипертензией. Евразийский кардиологический журнал 2015; 2: 42-49. eLIBRARY ID: 23754520

13. Мартынюк Т.В. Легочная гипертензия: Диагностика и лечение. Сер. Библиотека ФГБУ «НИМЦ кардиологии» Минздрава России.— М.: ООО «Медицинское информационное агентство». 2018. — 304 с. ISBN: 978-5-6040008-0-9

14. Мершин К.В., Акчурин Р.С. Хроническая тромбоэмболическая легочная гипертензия/ Глава в монографии «Легочная гипертензия» под ред. Чазовой И.Е., Мартынюк Т.В. — М: Практика. 2015. — С. 563–602. ISBN: 978-5-89816-138-5

15. Мершина Е.А., Синицын В.Е. Роль методов лучевой диагностики при постановке диагноза хронической тромбоэмболической легочной гипертензии. Атеротромбоз 2016; 1: 16-25. doi.org/10.21518/2307-1109-2016-1-16-25

16. Рябыкина Г.В., Блинова Е.В., Сахнова Т.А. Электровекторкардиографическая диагностика гипертрофии правого желудочка у больных легочной гипертензией. Медицинский алфавит 2017; 8: 3-17. eLIBRARY ID: 32368029

17. Сахнова Т.А., Блинова Е.В., Белевская А.А., др. Сопоставление интегральных показателей векторкардиограммы с данными эхокардиографического исследования у больных идиопатической и хронической тромбоэмболической легочной гипертензией. Терапевтический архив 2019; 3: 11-16. DOI: 10.26442/00403660.2019.03.000043

18. Таран И.Н., Белевская А.А., Валиева З.С., Саидова М.А., Мартынюк Т.В. «Портрет» пациентов с идиопатической легочной гипертензией и хронической тромбоэмболической легочной гипертензией в зависимости от коморбидного статуса: особенности течения заболевания и прогноз. Пульмонология. 2020;30(4) :427-36 DOI: 10.18093/0869-0189-2020-30-4-421-426

19. Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив 2014; 9: 4-23. eLIBRARY ID: 22599889

20. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., др. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии. (I ЧАСТЬ). Терапевтический архив 2016; 88 (9): 90-101. DOI: 10.17116/terarkh201688990-101

21. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., др. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии. (2 ЧАСТЬ). Терапевтический архив 2016; 88 (10): 63-74. DOI: 10.17116/terarkh201688663-73

22. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Оценка бремени хронической тромбоэмболической легочной гипертензии в Российской Федерации. Терапевтический архив 2018; 90 (9): 101-109. DOI: 10.26442/terarkh2018909101-109

23. Чазова И.Е., Валиева З.С, Наконечников С.Н., др. Особенности клинико-функционального и гемодинамического профиля, лекарственной терапии и оценка прогноза у пациентов с: неоперабельной хронической тромбоэмболической и: идиопатической легочной гипертензией по данным Российского регистра. Терапевтический архив 2019; 88 (10): 77-87. DOI: 10.26442/00403660.2019.09.000343

24. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2020; 1: 78-122. DOI: 10.38109/2225-1685-2020-1-78-122

25. Чернявский А. М., Едемский А. Г., Новикова Н. В., др. Применение радиочастотной абляции легочной артерии при лечении резидуальной легочной гипертензии после легочной эндартерэктомии. Кардиология 2018; 58 (4):15-21. https://doi.org/10.18087/cardio.2018.4.10105

26. Чернявский А.М., Едемский А.Г., Чернявский М.А., Караськов А.М. Глава «Хроническая тромбоэмболическая легочная гипертензия»/ Руководство «Легочная гипертензия». 2-е издание под редакцией С.Н. Авдеева. —М.: ГЭОТАР-Медиа 2019. —С. 365-418.

27. Хирургическое лечение хронической тромбоэмболической легочной гипертензии / А.М. Чернявский, А.Г. Едемский, Н.В. Новикова и др.; под общ. ред. А.М. Чернявского; ФГБУ «НМИЦ им. ак. Е.Н. Мешалкина» Минздрава России. - Новосибирск: Изд-во СО РАН, 2019. - 318 с.

28. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология 2016; 26 (1): 85-91. https://doi.org/10.18093/0869-0189-2016-26-1-85-91

29. Adams A, Fedullo PF. Postoperative management of the patient undergoing pulmonary endarterectomy. Semin Thorac Cardiovasc Surg. 2006; 18(3): 250-256. DOI: 10.1053/j.semtcvs.2006.09.002

30. Auger W.R., Moser K.M. Pulmonary flow murmurs: a distinctive physical sign found in chronic pulmonary thromboembolic disease, Clin. Res. 1989; 37:145A. doi.org/10.1148/radiology.182.2.1732955

31. Becattini C., Manina G., Busti C., et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 2010; 126 (1): e51–e56. DOI: 10.1016/j.thromres.2010.01.007

32. Benson D.G, Schiebler M.L, Repplinger M.D., et al. Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions. Br J Radiol 2017; 90 (1074): 553-563. doi: 10.1259/bjr.20160901

33. Bergin C.J., Sirlin S., Hauschildt J., et al. Chronic thromboembolism: diagnosis with helical CT and MR imaging with angiographic and surgical correlation. Radiology 1997;204: 695–702. doi.org/10.1148/radiology.204.3.9280245

34. Cannon J.E, Su L., Kiely D.G., et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom national cohort. Circulation 2016; 133: 1761–1771. DOI: 10.1161/CIRCULATIONAHA.115.019470

35. Ciurzynski M., Kurzyna M., Bochowicz A., et al. Long-term effects of acute pulmonary embolism on echocardiographic Doppler indices and functional capacity. Clin Cardiol 2004; Vol. 27: 693–697. DOI: 10.1002/clc.4960271207

36. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009; 33: 332-8. DOI: 10.1183/09031936.00092008

37. Corris P.A. National audit of pulmonary hypertension 2012. Leeds, UK: Health and Social Care Information Centre; 2013 [accessed 2016 May 9]. Available from: http://www.hscic.gov.uk/catalogue/PUB10535/nati-pulmhype-audi-2012-rep.pdf

38. Chazova I., Martynyuk T., Valieva Z., et al. Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. Biomed Res Int. 2020 Jun 14;2020:6836973. doi: 10.1155/2020/6836973.

39. Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 577. DOI: 10.1016/s0002-9343(01)00915-9

40. D’Armini A.M., Morsolini M., Mattiucci G., et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014; 148: 1005–1011. doi.org/10.1016/j.jtcvs.2014.06.052

41. Darocha S., Banaszkiewicz M., Pietrasik A., et al. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. Int J Cardiol. 2018; 269: 283-288. DOI: 10.1016/j.ijcard.2018.07.015

42. Delcroix M., Lang I., Pepke-Zaba J., et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133: 859–71. doi: 10.1161/CIRCULATIONAHA.115.016522

43. Escribano-Subias P., Blanco I., López-Meseguer M., et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur. Respi.J. 2012. —Vol. 40 (3).—P.596-603. DOI: 10.1183/09031936.00101211

44. Fedullo P.F., Auger W.R., Kerr K.M., Rubin L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472. DOI: 10.1056/NEJMra010902

45. Fisher M.R., Forfia P.R., Chamera E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 2009; 179: 615-621. DOI: 10.1164/rccm.200811-1691OC

46. Fukuda K., Hiroshi Date H., Doi S., et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019; 83 (4): 842-945. DOI: 10.1253/circj.CJ-66-0158

47. Fukui S., Ogo T., Morita Y., et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014; 43:1394–1402. DOI: 10.1183/09031936.00012914

48. Galie N., Humbert M., Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015

49. Gall H., Vachiéry J.L., Tanabe N. et al. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Lung 2018; 196: 305–312. DOI: 10.1007/s00408-018-0100-3

50. Ghofrani HA, Schermuly RT, Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139–1141. DOI: 10.1164/rccm.200210-1157BC

51. Ghofrani H.A., Hoeper M.M., Halank M., et al. Riociguat for chronic Thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; Vol. 36: 792–799. DOI: 10.1183/09031936.00182909

52. Ghofrani H.A., D’Armini A.M., Grimminger F., et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369 (4): 319-329. DOI: 10.1056/NEJMoa1209657

53. Ghofrani H.A., Simonneau G., D’Armini A.M., Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebocontrolled study./ Lancet. Respir. Med. — 2017. — Vol. 5 (10). — Р.785-794. DOI: 10.1016/S2213-2600(17)30305-3

54. Gopalan D., Delcroix M., Held M. Diagnosis of chronic thromboembolic pulmonary hypertension. Eur Respir Review 2017; 26: 160108. DOI: 10.1183/16000617.0108-2016

55. Grondelle A., Ditchey R.V., Groves B.M., et al. Thermodilution method overestimates low cardiac output in humans. Am J Physiol 1983. 245: H690–H692. DOI: 10.1152/ajpheart.1983.245.4.H690

56. Guerin L., Couturaud F., Parent F., et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Haemost 2014; 112: 598–605. DOI: 10.1160/TH13-07-0538

57. Guth S., Wiedenroth C.B., Wellenschlages M., et al. Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2018;155:643-9. DOI: 10.1016/j.jtcvs.2017.09.045

58. Hoeper M.M., Mayer E., Simonneau G. et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–2020. doi.org/10.1161/CIRCULATIONAHA.105.602565

59. Hoeper M.M., Ghofrani H.A., Al-Hiti H., et al. Switching from phosphodiesterase type 5 inhibitors to riociguat in patients with pulmonary arterial hypertension: The REPLACE study. E-POSTER (Nr 3802) presented on the ERS 2020 International Conference Virtual Platform. Available at: https://ers.conference2web.com/#!resources/late-breaking-abstractswitching-from-pde5i-to-riociguat-in-patients-with-pah-the-replacestudy-158fd49b-b44a-495f-929d-3d5212141655.

60. Jais X., D’Armini A.M., Jansa P., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects ininoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial./ J. Am. Coll. Cardiol. —2008. —Vol. 52. —Р.2127–2134. doi: 10.1016/j.jacc.2008.08.059.

61. Jais X, Brenot P, Bouvaist H, et al. Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J. 2019; 54:RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885

62. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76:1457–1464. DOI: 10.1016/s0003-4975(03)00828-2

63. Jenkins D., Mayer E., Screaton N., Madani M. State-of-the-art chronic thromboembolic pulmonary hypertension: diagnosis and management. Eur Respir Rev 2012;21:32–39. DOI: 10.1183/09059180.00009211

64. Jensen K.W., Kerr K.M., Fedullo P.F., et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009; 120: 1248–1254. DOI: 10.1161/CIRCULATIONAHA.109.865881

65. Kataoka M., Inami T., Hayashida K., et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 756 – 762. DOI: 10.1161/CIRCINTERVENTIONS.112.971390

66. Kim N.H., Delcroix M., Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018

67. Konstantinides C.V., Torbick A., Giancarlo Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–3080. DOI: 10.1093/eurheartj/ehn310

68. Korsholm K., Andersen A., Mellemkjær S., et al. Results from more than 20 years of surgical pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in Denmark. EurJ Cardiothorac Surg, 2017; 52(4):704-709. doi.org/10.1093/ejcts/ezx182

69. Kovacs G., Avian A., Pienn M., et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings? Am J Respir Crit Care Med 2014; 190: 252–257. DOI: 10.1164/rccm.201402-0269PP

70. Kramm T. et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Research in Cardiol 2018; 107 (6): 548-553. DOI: 10.1007/s00392-018-1215-5

71. Kramm T. et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J of Cardio-thoracic surgery 2005; 28 (6): 882-888. DOI: 10.1016/j.ejcts.2005.09.007

72. Lang I.M., Plank C., Sadushi-Kolici R., et al. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging 2010; 3: 1287–1295. doi.org/10.1016/j.jcmg.2010.09.013

73. Lang I., Simonneau G., Pepke-Zaba J., et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension: a case-control study. Thromb Haemost 2013; 110: 83–91. DOI: 10.1160/TH13-02-0097

74. Ley S., Ley-Zaporozhan J., Pitton M.B., et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012;22: 607–616. DOI: 10.1007/s00330-011-2290-4

75. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012; 94: 97–103. DOI: 10.1016/j.athoracsur.2012.04.004

76. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of nonischaemic cardiomyopathies. Eur Heart J 2005; 26 (15): 1461–1474. DOI:10.1093/eurheartj/ehi258

77. Mehta S., Helmersen D., Provencher S., et al. Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. Can Respir J. 2010; 17(6):301-34. DOI: 10.1155/2010/704258

78. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence based clinical practice guidelines. Chest 2004; 126: 14S–34S. DOI: 10.1378/chest.126.1_suppl.14S

79. Mueller-Mottet S., Stricker H., Domenighetti G et al. Long-term data from the Swiss pulmonary hypertension registry. Respiration 2015; 89:127–140. DOI: 10.1159/000370125

80. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702–10. DOI: 10.1016/j.jtcvs.2010.11.024

81. Neder J.A., Ramos R.P., Ota-Arakaki J.S., et al. Exercise intolerance in pulmonary arterial hypertension. The role of cardiopulmonary exercise testing. Ann Am Thorac Soc 2015; 12: 604–612. DOI: 10.1513/AnnalsATS.201412-558CC

82. Nishikawa T., Dohi S. Errors in the measurement of cardiac output by thermodilution. Can J Anaesth 1993; 40:142–153. DOI: 10.1007/BF03011312

83. Olschewski H., Simonneau G., Galie N., et al. for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347:322-329. DOI: 10.1056/NEJMoa020204

84. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350: 2257–2264. DOI: 10.1056/NEJMoa032274

85. Pepke-Zaba J., Delcroix M., Lang I., et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973–1981. doi.org/10.1161/CIRCULATIONAHA.110.015008

86. Pepke-Zaba J., Hoeper M.M., Humbert M. Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. Eur Respir J 2013; 41: 8–9. DOI: 10.1183/09031936.00181212

87. Pretorius V, Alayadhi W, Modry D. Extracorporeal life support for the control of life-threatening pulmonary hemorrhage. Ann Thorac Surg. 2009;88:649–50. DOI: 10.1016/j.athoracsur.2008.12.066

88. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. DOI: 10.1056/NEJMoa1213917

89. Reichenberger F., Voswinckel R., Enke B., et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007. 30: 922–927.DOI: 10.1183/09031936.00039007

90. Reesink H.J., van der Plas M.N., Verhey N.E., et al. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2007; 133: 510–516. DOI: 10.1016/j.jtcvs.2006.10.020

91. Romanov A., Cherniavskiy A., Novikova N., et al. Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy. JACC 2020; 76 (8): 916-26. DOI: 10.1016/j.jacc.2020.06.064

92. Saouti N, Morshuis WJ, Heijmen RH, Snijder RJ. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience. Eur J Cardiothorac Surg. 2009; 35:947–952. doi: 10.1016/j.ejcts.2009.01.023.

93. Shah S., Boyd G., Pyne C.T., et al. Right heart catheterization using antecubital venous access: feasibility, safety and adoption rate in a tertiary center. Catheter Cardiovasc Interv 2014; 84 (1): 70-74. DOI: 10.1002/ccd.25249

94. Simonneau G., D’Armini A.M., Ghofrani H.A., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a longterm extension study (CHEST-2). Eur Respir J, 2015 May, 45(5): 1293-302. DOI: 10.1183/09031936.00087114

95. Skoro-Sajer N., Marta G., Gerges C., et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax 2014;.69:116–122. DOI: 10.1136/thoraxjnl-2013-203746

96. Stasch J.P., et al. Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation 2011; 123: 2263-2274. DOI: 10.1161/CIRCULATIONAHA.110.981738

97. Sugimura K, Fukumoto Y, Satoh K., et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012; 76: 485– 488. DOI: 10.1253/circj.cj-11-1217

98. Sugiyama M., Fukuda T., Sanda Y., et al. Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension; imaging with cone beam computed tomography. Jpn J Radiol 2014; 32:375 – 382. DOI: 10.1007/s11604-014-0319-8

99. Surie S, Tijssen MA, Biervliet JD et al. Chorea in adults following pulmonary endarterectomy. Mov Disord. 2010 Jun 15;25(8):1101-4. DOI: 10.1002/mds.23044

100. Suntharalingam J., Treacy C.M., Doughty N.J., et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134: 229–2. https://doi.org/10.1378/chest.07-2681

101. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 2014; 44: 1635–1645. DOI: 10.1183/09031936.00050114

102. Taran I., Belevskaya A.A., Saidova M.A., Martynyuk T.V., Chazova I.E. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung 2018; 196:745–753. DOI: 10.1007/s00408-018-0160-4

103. Taran I., Valieva Z.S., Belevskaya A.A., Saidova M.A., Martynyuk T.V., Chazova I.E. Features of the disease in patients with precapillary pulmonary hypertension with essential hypertension and carbonhydrate metabolism disorders. Journal of Hypertension 2019; 37: e203. doi: 10.1097/01.hjh.0000572616.51506.ca.

104. Tsai C.H., Wu C.K., Kuo P.H., et al. Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Аcta Cardiol. Sin 2020; 36 (1): 64-71. DOI: 10.6515/ACS.202001_36(1).20190612A

105. Tunariu N., Gibbs S., Win Z., et al. Ventilation-perfusion scintigraphy Is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680–684. DOI: 10.2967/jnumed.106.039438

106. van Thor M.C., Ten Klooster L., Snijder R.J., et al. Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension. Int J Cardiol Heart Vasc 2019; 22: 163-168. DOI: 10.1016/j.ijcha.2019.02.004

107. Wagenvoort C.A. Pathology of pulmonary thromboembolism. Chest 1995; 107: 10S–17S. DOI: 10.1378/chest.107.1_supplement.10s

108. Wilkens H, Lang I, Behr J, et al. Chronic thromboembolic pulmonary hypertension: Recommendations from the Cologne Consensus Conference 2010.Dtsch Med Wochenschr 2010;135(Suppl 3):S125–30 https://doi.org/10.1016/S0167-5273(11)70493-4

109. Wilkens, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol. 2018; 272: 69-78. DOI: 10.1016/j.ijcard.2018.08.079

110. Yamamoto K., Tanabe N., Suda R., et al. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor. Respir Investig 2017; 55 (4): P.270-275. https://doi.org/10.1016/j.resinv.2017.04.004

111. Zhai Z, Murphy K, Tighe H,et al. Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2011; 140: 1284–1291. https://doi.org/10.1378/chest.10-3357

112. Zoreka et al. Pulmonary Capillary Wedge Pressure Measurement: A Challenge for Diagnosis of Pulmonary Arterial Hypertension. Int J Respir Pulm Med 2015; 2: 010.

113. AMBER-1. https://clinicaltrials.gov/ct2/show/NCT01884675/